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PRELIMINARY AND SHORT REPORTS
PSORIASIS TREATED BY RIBOFLAVIN
MERLIN T-R. MAYNARD, M.D.
It is with considerable hesitancy that I add to the already too long list of treatments for
psoriasis, and I would not do so were it just another local treatment. I present this paper
in the hope that it is a contribution to the knowledge of psoriasis as a disease, and that fur-
ther fruitful study may result.
This series was started through the finding that many psoriasiform eruptions, clinically
typical, associated with riboflavin deficiencies responded rapidly to injections of this sub-
stance, and that other cases, even without obvious deficiency, also commonly improved.
There appears to be nothing in the literature since riboflavin has been known as a com-
ponent of the vitamin B complex to indicate that it has been similarly used.
I located one article published in 1942, in the Schweiz. Med. Woehensehrift (1), in which
the author found that riboflavin was demonstrated in increased amounts in the plaques and
scales of psoriasis by spectrometer examination: this is hard to explain, and on its face
would seem to be a possible contra-indication to the use of riboflavin in the treatment of
the disease.
At the time of the writing of this paper I have treated over two hundred eases, but due
to incomplete follow up have only one hundred and forty-eight such eases on which to base
this study. All these eases were given injections of riboflavin (5-10 mgm. intramuscularly,
usually once weekly) as a basic treatment. It has also been given orally in daily dosage co-
incident with the injections. In all eases local treatment has been dispensed with until
proof of the patient's response is established, and then only used on "survival lesions," or
in a few instances for faster cosmetic effect.
The statistics of the eases treated from my own observation are as follows
Number of eases 148
Healed 37 25%
Marked improvement (80% or better) 70 52%
Improved (50% or more) 25 lfi%
Slight improvement (less than 50%) 4 3%
Failed to respond fi 4%
Worse None
One hundred and fifty-six cards were then sent to patients in the original series who had
not been seen in 2 or more years requesting information as to their present condition. No
attempt was made to figure the time since the patient was last seen. The complexity of such
a statistical breakdown can be surmised. Cases under current observation were not re-
corded.
Cards sent 150
Cards returned 50
Patient's evaluation:
Condition recurred about as before treat-
ment
Improvement sustained. No relapse
Improved but relapsed partially
Healed
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propose to get a series of biopsy studies during treatments, and bope thnt others will
do this likewise, as eonsidernble information may be made available. Enzyme and chemical
studies would also be of great value. Certainly this is a very incomplete study and must be
considered pre1iminary to further research.
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